Beijing Bohui Innovation Biotechnology Group Co., Ltd. ("Bohui Group"), founded in 2001, has evolved into a high-tech biomedical enterprise that integrating R&D, production, sales, and after-sales service. Headquartered in Zhongguancun Life Science Park in Beijing, the company operates a 40,000 square-meter comprehensive R&D center. In May 2012, Bohui Group was listed on the Shenzhen Stock Exchange ChiNext (Stock Code: 300318).

Demystifying Enzymatic Synthesis: Why It's the Gold Standard for Injectable-Grade NAD+? The NAD+ therapy market is booming, but the choice of manufacturing process directly dictates the upper limit of product safety and efficacy. ⚗️ Chemical synthesis involves complex pathways, easily introducing unknown impurities and organic solvent residues, posing potential risks for IV injection. In contrast, Enzymatic Biocatalysis, adopted by Howa Biotech, mimics the natural in-vivo synthesis pathway and offers unparalleled advantages: ✅ Ultra-High Purity: Achieves ≥99% main purity effortlessly with a clear and controllable impurity profile. ✅ Extremely Low Endotoxin: Consistently controlled at <0.2 EU/mg, far exceeding injectable-grade standards. ✅ High Bioactivity: Correct spatial structure ensures biological function. For pharmaceutical companies and high-end clinics, choosing a raw material supplier is choosing a risk-control partner. Advanced technology is the first line of defense for safety. sales@horwats.com +86 19052754932(whatsapp) #NAD #IVTherapy #Biotechnology #cGMP #EnzymaticSynthesis